Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A

@inproceedings{Sherman2017InnovativeAF,
  title={Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A},
  author={Alexandra Sherman and Moanaro Biswas and Roland W. Herzog},
  booktitle={Front. Immunol.},
  year={2017}
}
Hemophilia A (coagulation factor VIII deficiency) is a debilitating genetic disorder that is primarily treated with intravenous replacement therapy. Despite a variety of factor VIII protein formulations available, the risk of developing anti-dug antibodies ("inhibitors") remains. Overall, 20-30% of patients with severe disease develop inhibitors. Current clinical immune tolerance induction protocols to eliminate inhibitors are not effective in all patients, and there are no prophylactic… CONTINUE READING